Figure 2. Glycemic Outcomes.

A, Changes in hemoglobin A_1c (HbA_1c) concentration from baseline to 16 weeks. The adjusted least-squares mean (LSM) changes were intermittent fasting plan consisting of 2 nonconsecutive fasting days and 5 days of habitual intake per week and meal replacement diet (5:2 MR), −1.9% (SE, 0.2%); metformin, −1.6% (SE, 0.2%); and empagliflozin, −1.5% (SE, 0.2%) (to convert to proportion of total hemoglobin, multiply by 0.01). The adjusted LSM difference between 5:2 MR and metformin was −0.3% (95% CI, −0.5% to 0.1%), and the adjusted LSM difference between 5:2 MR and empagliflozin was −0.4% (95% CI, −0.6% to 0.2%). B, Changes in HbA_1c concentration from baseline to 16 weeks in patients with overweight or obesity. C, Percentage of patients with HbA_1c concentrations of less than 7.0% or of less than 6.5% at week 16. D, Changes in fasting plasma glucose (FPG) concentrations from baseline to 16 weeks (to convert glucose to millimoles per liter, multiply by 0.0555). Error bars display SEs.